Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia

British Journal of Ophthalmology

Volumn 92, Issue 7, 2008, Pages 941-945

  Charbel Issa, P ^a   Finger, R P ^a   Holz, F G ^a   Scholl, H P N ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; BIOMICROSCOPY; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULOPATHY; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TELANGIECTASIA; TREATMENT DURATION; TYPE 2 IDIOPATHIC MACULAR TELANGIECTATASIA; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACULA LUTEA; MALE; MIDDLE AGED; RETINAL DISEASES; RETINAL VESSELS; RETROSPECTIVE STUDIES; TELANGIECTASIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 47049093513     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.129627     Document Type: Article

References (13)

1. Charbel Issa P, Scholl HPN, Helb HM, et al. Idiopathic macular telangiectasia. In: Holz FG, Spaide RF, eds. Medical retina. 2nd edn. Berlin: Springer, 2007:183-97.
2. Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 1993;100:1536-46.
3. Yannuzzi LA, Bardal AM, Freund KB, et al. Idiopathic macular telangiectasia. Arch Ophthalmol 2006;124:450-60.
4. Gaudric A, Ducos de LG, Cohen SY, et al. Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 2006;124:1410-19.
5. Paunescu LA, Ko TH, Duker JS, et al. Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography. Ophthalmology 2006;113:48-57.
6. Charbel Issa P, Helb HM, Rohrschneider K, et al. Microperimetric assessment of patients with type II macular telangiectasia. Invest Ophthalmol Vis Sci 2007;48:3788-95.
7. Charbel Issa P, Scholl HPN, Holz FG. Intravitreal bevacizumab for the treatment of type 2 idiopathic macular telangiectasis. Retinal Cases Brief Rep 2007;1:189-91.
8. Charbel Issa P, Holz FG, Scholl HPN. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 2007;114:1736-42.
9. Beer PM, Wong SJ, Hammad AM, et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006;26:871-6.
10. Cohen SM, Cohen ML, El-Jabali F, et al. Optical coherence tomography findings in nonproliferative group 2A idiopathic juxtafoveal retinal telangiectasis. Retina 2007;27:59-66.
11. Charbel Issa P, Helb HM, Holz FG, et al. Correlation of macular function with retinal thickness in nonproliferative type 2 idiopathic macular telangiectasia. Am J Ophthalmol 2008;245:169-75.
12. Kim I, Ryan AM, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 1999;40:2115-21.
13. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.